EGFR and neoplasm: Genetic alterations in cancer cells are associated with tumor progression and metastasis, and there is evidence that KRAS, epidermal growth factor receptor (EGFR) and TP53 mutations are associated with relapse or worse survival outcomes in patients with early lung adenocarcinoma (3, 4).